Skip to main content
Log in

Die Bestimmung des PSA-Nadirs nach Strahlentherapie kann die Dosissteigerungsstudie an Patienten mit prätherapeutischen PSA-Werten < 10 ng/ml nicht bestätigen

  • Literatur Kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Hanks, G. E., T. E. Schultheiss, A. L. Hanlon et al.: Optimization of conformal radiation treatment of prostate cancer, report of a dose escalation study. In press.

  2. Herold, D., G. Hanks, B. Movsas et al. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values <10 ng/ml. Radiat. Oncol. Invest. 5 (1997), 15–19.

    Article  CAS  Google Scholar 

  3. Lee, W. R., A. L. Hanlon, G. E. Hanks: Prostate specific antigen nadir following external beam radiation therapy for clinically localizend prostate cancer, the relationship between nadir level and disease-free survival. In press.

  4. Tibbs, M. K., A. L. Zietman, K. C. Dallow et al. Biochemical out-come following external beam radiation therapy for T1-2 prostate carcinoma: the importance of achieving an undetectable nadir PSA. Int. J. Radiat. Oncol. Biol. Phys. 32 (1995), 230.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sack, H. Die Bestimmung des PSA-Nadirs nach Strahlentherapie kann die Dosissteigerungsstudie an Patienten mit prätherapeutischen PSA-Werten < 10 ng/ml nicht bestätigen. Strahlenther. Onkol. 173, 529 (1997). https://doi.org/10.1007/BF03038470

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03038470

Navigation